Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs supply extensive range of anti-AFP CAR related products and one-stop solution to support our clients’ CART development. Please browse the following list to find the products you need.
Alpha-fetoprotein (AFP) is a tumor-associated fetal mammalian glycoprotein involved in a variety of biological processes, including regulation of cell proliferation, migration, apoptosis, immune escape, and induction of malignant transformation of cancer cells. Studies have shown that AFP is closely related to the occurrence of a variety of tumors, and can be used as a clinical biomarker and prognostic indicator for the diagnosis of carcinomas.
Fig.1 Schematic diagram of AFP binding to AFP receptors promoting malignant transformation of cancer cells.1
Anti-AFP CAR-T Expression Test
Creative Biolabs has developed multiple CAR detection reagents (such as target-specific CAR detection reagents, linker-specific antibodies), and established various approaches to test CAR expression.
Anti-AFP CAR-T Phenotype Analysis
To characterize the capability of AFP-CAR T cells, Creative Biolabs has developed a comprehensive phenotypic assessment service to test the proliferation, stimulation, and degranulation activity of CART cells. For anti-AFP CAR-T phenotype analysis, CD107a surface expression as a measurement marker to test the degranulation activity by flow cytometry.
Fig.2 CD107a expression detection of AFP-CAR+ CD8+ T cells incubated with different tumor cells at 5:1 E:T ratio by flow cytometry.2
Anti-AFP CAR-T Cytokine Release Test
To assess the cytokine releasing capability of CART cells co-cultured with target cells, we supply many suitable approaches for cytokine detection, such as multiplex cytokine array, and intracellular cytokine test by flow cytometry.
Multiplex ELISA to test cytokine secretion
Fig.3 Cytokine secretion measurements of AFP CAR-T cells co-cultured with different tumor cells by multiplex ELISA.2
Flow cytometry analysis to assess intracellular cytokine
Fig.4 Cytokine measurements of AFP CAR-T cells co-cultured with different tumor cells detected by intracellular staining.2
Anti-AFP CAR-T In Vitro Cytotoxicity Assay
We offer a variety of robust and sensitive methods to evaluate the antigen specificity and antitumor activity of CART cells incubated with target cells, including but not limited to LDH release assay, real-time cell analysis (RTCA), and cytotoxicity test by flow cytometry.
Fig.5 The cytotoxicity evaluation of AFP CAR-T cells against target A2+/AFP+ cells at 5:1 E:T ratio detected by LDH release assay.2
Anti-AFP CAR-T Cell Therapy Animal Models
Creative Biolabs is committed to providing one-stop services for CART development, including in vivo related items, such as off-the-shelf and customized animal models, as well as optimized in vivo experimental design.
Efficacy Test of Anti-AFP CAR-T
To assess the in vivo antitumor activity of CAR T cells in appropriate animal models, Creative Biolabs provides optimized experimental design and detection solutions for global customers to support CAR development. For all in vivo experiments, we test each batch of CART cells in an in vitro cytotoxicity assay to ensure batch-to-batch with low variation before in vivo administration.
Fig.6 The antitumor evaluation of anti-AFP CAR-T in the disseminated peritoneal liver cancer model detected by luciferase photon emission.2
Toxicity Evaluation Anti-AFP CAR-T
To monitor and evaluate the safety of CART treatment, we have launched a comprehensive range of evaluation solutions for target-specific CART projects. Our robust CAR-T evaluation services include, but are not limited to, tissue phenotype analysis of in vivo models with CART treatment, and off-toxicity studies.
References
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-ZP2982 | Anti-AFP (C3) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | C3 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-SB-LX0009 | Anti-AFP (5F11) h(CD28-CD3ζ) CAR, pSBCAR1 | Human | 5F11 | Mouse | scFv-CD28-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| CAR-SB-LX0010 | Anti-AFP (Tacatuzumab) h(CD28-CD3ζ) CAR, pSBCAR1 | Human | Tacatuzumab | Mouse | scFv-CD28-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0622-ZP3186 | Anti-AFP h(VHH1-VHH2-CD28-CD3ζ) Biepitopic CAR, pCDCAR1 | Human | VHH1-VHH2-CD28-CD3ζ | Lentiviral vector | T Cell | ||||
| XS-1122-YF3 | Anti-AFP KIR CAR (scFv-KIR2DS2-DAP12, XW-03), pCDCAR1 | Human | XW-03 | Mouse | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
| XS-1122-YF923 | Anti-AFP TCR-ABR (scFv-TCRα, XW-03) CAR Plasmid, pCDCAR1 | Human | XW-03 | Mouse | scFv-TCRα | Lentiviral vector | T Cell | ||
| XS-1122-YF1843 | Anti-AFP TCR-ABR (scFv-TCRβ, XW-03) CAR Plasmid, pCDCAR1 | Human | XW-03 | Mouse | scFv-TCRβ | Lentiviral vector | T Cell | ||
| XS-1122-YF7363 | Anti-AFP (XW-03) h(CD28-41BB-CD3ζ) CAR, pAAV | Human | XW-03 | Mouse | scFv-CD28-41BB-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
| XS-1122-LX407 | Anti-AFP (X11X9) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X9 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX408 | Anti-AFP (X11X10) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X10 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX409 | Anti-AFP (X11X11) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X11 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX410 | Anti-AFP (X11X12) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X12 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX805 | Anti-AFP (X11X9) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | X11X9 | Humanized | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX806 | Anti-AFP (X11X10) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | X11X10 | Humanized | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX807 | Anti-AFP (X11X11) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | X11X11 | Humanized | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX808 | Anti-AFP (X11X12) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | X11X12 | Humanized | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-0123-ZP124 | Anti-AFP (Tacatuzumab) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | Tacatuzumab | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0323-ZP124 | Anti-AFP (Tacatuzumab scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | Tacatuzumab | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
